Partex and Fortress Biotech Announce Strategic Collaboration to Accelerate Asset Identification and Evaluation Using Proprietary AI Platform

Core Insights - Partex NV and Fortress Biotech, Inc. have announced a strategic collaboration to utilize artificial intelligence in identifying and evaluating biopharmaceutical compounds for potential acquisition or licensing by Fortress [1][4]. Company Overview - Partex is an AI-driven biopharmaceutical company focused on revolutionizing drug discovery and development, aiming to accelerate the identification and commercialization of breakthrough therapies [5]. - Fortress Biotech is an innovative biopharmaceutical company that focuses on acquiring and advancing assets to enhance long-term shareholder value through product revenue, equity holdings, and dividend and royalty revenue [6]. Collaboration Details - Partex will deploy its proprietary AI-based drug discovery platform, which provides diverse recommendations on alternative targets and helps evaluate compounds across various therapeutic areas [2]. - The collaboration aims to leverage the strengths of both companies, combining Fortress's expertise in clinical development with Partex's advanced AI platform to enhance the efficiency of identifying and evaluating biopharmaceutical assets [3][4]. - The partnership is expected to expedite the search and evaluation process for differentiated assets, utilizing AI to maximize potential opportunities [4]. Business Development Focus - Fortress is focused on expanding its portfolio and business development opportunities, with a robust late-stage pipeline and the recent launch of two approved medicines [4]. - The collaboration with Partex is seen as a means to scale operations more efficiently and cost-effectively, enhancing long-term value for shareholders [4].